Table 1

Subjects' anthropometric and laboratory characteristics at baseline and after 26 weeks of treatment.

Pioglitazone
Insulin glargine
Δ pioglitazone vs. Δ insulin glargine
P

Week 0
 Week 26
 P
 Week 0
 Week 26
 P

15
15

Men/women
 11/4
9/6

Age(years)
 60.8 ± 7.1
61.5 ± 8.2

Diabetes Duration (years)
 11.1 ± 6
9.5 ± 7.5

BMI (kg/m2)
 30.8 ± 5.5
 31.9 ± 5.9
 0.001
 31.6 ± 6.1
 32.5 ± 6.2
 0.01
 0.37
HbA1c (%)
 8.1 ± 1.5
 6.8 ± 1.2
 0.001
 8.3 ± 1.4
 6.1 ± 0.7
 0.001
 0.23
Haemoglobin (g/l)
 137.5 ± 11.4
 127 ± 12.0
 0.001
 137.1 ± 10.2
 132 ± 12.0
 0.02
 0.13
Cholesterol (mmol/l)
 4.4 ± 0.9
 4.2 ± 0.7
 0.17
 4.3 ± 1.0
 4.1 ± 1.0
 0.32
 0.65
HDL (mmol/l)
 1.1 ± 0.2
 1.3 ± 0.3
 0.01
 1.1 ± 0.4
 1.1 ± 0.4
 0.49
 0.01
LDL (mmol/l)
 2.4 ± 0.9
 2.3 ± 0.5
 0.64
 2.3 ± 0.7
 2.4 ± 0.7
 0.46
 0.48
TG (mmol/l)
 1.8 ± 0.8
 1.5 ± 1.0
 0.002
 1.9 ± 1.3
 1.5 ± 1.0
 0.009
 0.43
ALT (μcat/l)
 0.7 ± 0.7
 0.4 ± 0.3
 0.04
 0.5 ± 0.2
 0.5 ± 0.2
 0.12
 0.87
Systolic blood pressure
 142 ± 16
 134 ± 10
 0.04
 146 ± 17
 132 ± 13
 0.02
 0.39
Diastolic blood pressure
 84 ± 8
 77 ± 7
 0.02
 81 ± 8
 73 ± 8
 0.007
 0.57
BNP (pmol/l)
 6.9 ± 5.2
 14.1 ± 16.7
 0.10
 9.7 ± 12.9
 9.7 ± 11.6
 0.41
 0.51
NT-proBNP (ng/l)
 11.4 ± 19.6
 22.8 ± 44.0
 0.046
 13.6 ± 20.0
 10.1 ± 9.5
 0.97
 0.23

Values are mean ± SD. There were no significant differences between subjects' characteristics at start or after 26 weeks of treatment.

Dorkhan et al. Cardiovascular Diabetology 2009 8:15   doi:10.1186/1475-2840-8-15